	US 11,999,780 B2
	Humanized anti-complement factor Bb antibodies and uses thereof
Graham Parry, Burlington, MA (US); Stephen Moore, Danville, CA (US); Michael Storek, Bridgewater, NJ (US); and Nina C. Leksa, Bridgewater, NJ (US)
Assigned to Genzyme Corporation, Cambridge, MA (US)
Filed by Genzyme Corporation, Cambridge, MA (US)
Filed on Dec. 21, 2021, as Appl. No. 17/557,318.
Application 17/557,318 is a division of application No. 17/234,618, filed on Apr. 19, 2021, granted, now 11,242,382.
Claims priority of provisional application 63/012,590, filed on Apr. 20, 2020.
Prior Publication US 2022/0213179 A1, Jul. 7, 2022
Int. Cl. C07K 16/18 (2006.01); A61K 39/00 (2006.01); A61K 47/68 (2017.01); A61P 13/00 (2006.01)

CPC C07K 16/18 (2013.01) [A61K 47/6843 (2017.08); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/92 (2013.01)]

17 Claims

1. A nucleic acid or nucleic acid set encoding a humanized antibody that binds specifically to human complement factor Bb protein, wherein the humanized antibody comprises: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 19 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 27.